Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT02481622
NCT02481622UnknownNot Applicable

Inhibition by the Antibody, First Event of Infection by HIV-1 of Uterine Vaginal Tissue

University Hospital, Strasbourg, France1 site in 1 country600 target enrollmentStarted: November 2015Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Sponsor
Enrollment
600
Locations
1
Primary Endpoint
identification of the first HIV-infected cells by a histological analysis
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This non-interventional study aims to characterize the cells infected with HIV over time in different types of vagino-uterine tissue.

Study Design

Study Type
Observational
Observational Model
Other
Time Perspective
Retrospective

Eligibility Criteria

Ages
18 Years to 50 Years (Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Patients whose age ≤50 years and ≥18 years
  • •Patients for which surgery like laparoscopy or hysterectomy is necessary as part of a benign pathology.

Exclusion Criteria

  • •Patients under 18 years

Outcomes

Primary Outcomes

identification of the first HIV-infected cells by a histological analysis

Time Frame: after surgery, up to 3 weks

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
University Hospital, Strasbourg, France
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Recruiting
Not Applicable
SCOPE Analytic Treatment Interruption ProtocolHIV/AIDS
NCT04359186University of California, San Francisco40
Completed
Phase 4
Pilot Opened Trial in HIV-infected Patients Including an Investigational Marketed ProductHIV Infections
NCT00773708Germans Trias i Pujol Hospital57
Completed
Phase 2
Chloroquine for Reducing Immune Activation in HIV- Infected IndividualsHIV Infections
NCT00819390Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections70
Terminated
Phase 2
HIV Immune and Virological Responses Following the Administration of IL-2 Either Alone or Combined to ALVAC-HIV 1433 and HIV Lipopeptides in Patients Treated Early With HAART During Primary InfectionHIV Infection
NCT00196651French National Agency for Research on AIDS and Viral Hepatitis60
Completed
Not Applicable
Observing Patients With Early HIV InfectionHIV Infections
NCT00005020National Institute of Allergy and Infectious Diseases (NIAID)10
First Event of Infection by HIV-1 of... | Clinical Trial